Analyst: Novartis's Kesimpta sales exceeded expectations

Genmab may upgrade its financial guidance after the biotech company's partner made more sales than expected of sclerosis drug Kesimpta, a Sydbank analyst predicts.

Photo: Sydbank/PR

Novartis's sales of Genmab-developed drug Kesimpta were better than both the analyst consensus estimate and Sydbank's prediction, which could mean an upgrade to its financial guidance is on the way from Genmab, Senior Analyst Søren Løntoft Hansen states.

Novartis released its Q3 report on Tuesday, revealing that net sales of its scleoris drug totaled USD 109m, which exceeds Sydbank's estimate of USD 90m. The consensus estimate of several analysts collected by Genmab itself was also USD 90m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs